Inclusion Criteria:

- Metastatic melanoma with measurable disease after attempted curative surgical therapy
and who have received at least one prior chemotherapy regimen; adjuvant interferon or
isolated limb perfusion is allowed.

- Tumor tissue must be available for immunohistochemical analysis, and specimens will
stained for MART-1 by immunohistochemical staining and will also be stained for
HMB-45 by immunohistochemistry, and positivity for at least one will be an entry
requirement.

- Patients must be HLA-A *0201 positive, by a DNA SSOP analysis.

- Serum creatinine of 2.0 mg/dl or less, total bilirubin of 2.0 mg/dl or less, and
ALT/AST of less than 3X institutional upper limit of normal.

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Patients must be able to understand and sign an IRB approved informed consent form.

- Patients must have white blood count of 3000 or greater, platelets of 100,000 or
greater, and hemoglobin of 9.0 gm/dl or more.

- Patients with unresectable stages III/IV uveal melanoma and metastatic mucosal
melanoma will be eligible for this trial.

Exclusion Criteria:

- Undergoing or have undergone in the past month any other therapy for their melanoma,
including radiation therapy, chemotherapy and adjuvant therapy

- Have major systemic infections, coagulation disorders, or other major medical
illnesses of the cardiovascular or respiratory systems, or have had a documented MI
in the last 6 months

- Require steroid therapy

- Patients who are pregnant or lactating

- Known to be positive for hepatitis BsAg, Hepatitis C or HIV antibody

- Have a prior history of uveitis or autoimmune inflammatory eye disease

- Have had another malignancy other than cervical carcinoma-in-situ or basal cell
/squamous cancer of the skin, unless they have undergone curative therapy more than 3
years ago and are still free of detectable disease, since the effects of
peptide-pulsed DC on other active cancers are unknown